Overview

Study of FK463 for the Treatment of Invasive Aspergillosis

Status:
Completed
Trial end date:
2002-01-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Micafungin